ConductScience.org, home

Paper21397538

Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.

Koeberl DD and 8 others. Mol Genet Metab, 2011. Cited by 63 papers, by iCite.

Cite this record

ConductScience Library. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Papers, record 21397538. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21397538

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.
PubMed
Journal
Mol Genet Metab
PubMed
Year
2011
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
63
iCite
Relative citation ratio, by iCite
1.86
iCite
Revised in PubMed
2025-05-29
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Koeberl DDDwight D
2Luo XXiaoyan
3Sun BBaodong
4McVie-Wylie AAlison
5Dai JJian
6Li SSongtao
7Banugaria SGSuhrad G
8Chen YTY-T
9Bali DSDeeksha S

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Enzyme Replacement TherapyMajor topic
Glycogen Storage Disease Type IIMajor topic
Muscle, SkeletalMajor topic
Receptor, IGF Type 2Major topic
Adrenergic beta-Agonists
Animals
Clenbuterol
Disease Models, Animal
Glycogen
Male
Mice
Mice, Knockout
Motor Activity
alpha-Glucosidases

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 HL081122NHLBI NIH HHSUnited StatesR01HL081122PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT01942590Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement TherapyBackground

Source ClinicalTrials.gov

Download CSV of trials

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110430861Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase.Proc Natl Acad Sci U S A1999https://conductscience.org/library/papers/10430861PubMed
212507915Tissue-specific inactivation of murine M6P/IGF2R.Am J Pathol2003https://conductscience.org/library/papers/12507915PubMed
311808348[Adult form of acid maltase deficiency presenting with pattern of muscle weakness resembling facioscapulohumeral dystrophy].Rinsho Shinkeigaku2001https://conductscience.org/library/papers/11808348PubMed
415585406Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.Mol Ther2005https://conductscience.org/library/papers/15585406PubMed
515190196Enzyme replacement and enhancement therapies for lysosomal diseases.J Inherit Metab Dis2004https://conductscience.org/library/papers/15190196PubMed
618391178Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease.Physiol Rev2008https://conductscience.org/library/papers/18391178PubMed
715839836Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.Biochem J2005https://conductscience.org/library/papers/15839836PubMed
814567965Enzyme replacement therapy in the mouse model of Pompe disease.Mol Genet Metab2003https://conductscience.org/library/papers/14567965PubMed
917151143Extracellular signal-regulated kinase pathway is differentially involved in beta-agonist-induced hypertrophy in slow and fast muscles.Am J Physiol Cell Physiol2007https://conductscience.org/library/papers/17151143PubMed
1011739080Role of IGF-I and IGFBPs in the changes of mass and phenotype induced in rat soleus muscle by clenbuterol.Am J Physiol Endocrinol Metab2002https://conductscience.org/library/papers/11739080PubMed
1119277015Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease.Mol Ther2009https://conductscience.org/library/papers/19277015PubMed
1219649685Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.J Neurol2010https://conductscience.org/library/papers/19649685PubMed
1316432501Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.Br J Pharmacol2006https://conductscience.org/library/papers/16432501PubMed
149844629A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance.Mol Cell1998https://conductscience.org/library/papers/9844629PubMed
1515585405Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.Mol Ther2005https://conductscience.org/library/papers/15585405PubMed
169668092Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II.J Biol Chem1998https://conductscience.org/library/papers/9668092PubMed
172481447Effects of clenbuterol and propranolol on muscle mass. Evidence that clenbuterol stimulates muscle beta-adrenoceptors to induce hypertrophy.Biochem J1989https://conductscience.org/library/papers/2481447PubMed
1820817528Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study.Neuromuscul Disord2010https://conductscience.org/library/papers/20817528PubMed
1917093970Molecular impact of clenbuterol and isometric strength training on rat EDL muscles.Pflugers Arch2007https://conductscience.org/library/papers/17093970PubMed
2014677650Therapeutic clenbuterol treatment does not alter Ca2+ sensitivity of permeabilized fast muscle fibres from exercise trained or untrained horses.J Muscle Res Cell Motil2003https://conductscience.org/library/papers/14677650PubMed

See all 31 referencesDownload CSV of references

Cited by45

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 63 citations.

PMIDTitleJournalYearIn PapersSource
41199666Effects of hypoxia and hyperoxia on exercise-induced metabolomic and transcriptomic profiles in equine skeletal muscle.J Exp Biol2025https://conductscience.org/library/papers/41199666PubMed
38948331Base editing rescues acid α-glucosidase function in infantile-onset Pompe disease patient-derived cells.Mol Ther Nucleic Acids2024https://conductscience.org/library/papers/38948331PubMed
38232139Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders.Sci Transl Med2024https://conductscience.org/library/papers/38232139PubMed
37686045Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement.Int J Mol Sci2023https://conductscience.org/library/papers/37686045PubMed
37463048AAV-mediated delivery of secreted acid α-glucosidase with enhanced uptake corrects neuromuscular pathology in Pompe mice.JCI Insight2023https://conductscience.org/library/papers/37463048PubMed
36911201A universal GlycoDesign for lysosomal replacement enzymes to improve circulation time and biodistribution.Front Bioeng Biotechnol2023https://conductscience.org/library/papers/36911201PubMed
36805083Phase I study of liver depot gene therapy in late-onset Pompe disease.Mol Ther2023https://conductscience.org/library/papers/36805083PubMed
36138713The Clinical Management of Pompe Disease: A Pediatric Perspective.Children (Basel)2022https://conductscience.org/library/papers/36138713PubMed
35682977Isogenic GAA-KO Murine Muscle Cell Lines Mimicking Severe Pompe Mutations as Preclinical Models for the Screening of Potential Gene Therapy Strategies.Int J Mol Sci2022https://conductscience.org/library/papers/35682977PubMed
35411297To detect potential pathways and target genes in infantile Pompe patients using computational analysis.Bioimpacts2022https://conductscience.org/library/papers/35411297PubMed
35081735Efficacious Androgen Hormone Administration in Combination with Adeno-Associated Virus Vector-Mediated Gene Therapy in Female Mice with Pompe Disease.Hum Gene Ther2022https://conductscience.org/library/papers/35081735PubMed
34606154Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease.EMBO Mol Med2021https://conductscience.org/library/papers/34606154PubMed
34565280Carnitine is a pharmacological allosteric chaperone of the human lysosomal α-glucosidase.J Enzyme Inhib Med Chem2021https://conductscience.org/library/papers/34565280PubMed
34400331Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies.Mol Ther2021https://conductscience.org/library/papers/34400331PubMed
33953320Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease.Commun Biol2021https://conductscience.org/library/papers/33953320PubMed
33304924CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges.Front Mol Biosci2020https://conductscience.org/library/papers/33304924PubMed
32962155Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.Biomolecules2020https://conductscience.org/library/papers/32962155PubMed
31796685Advancements in AAV-mediated Gene Therapy for Pompe Disease.J Neuromuscul Dis2020https://conductscience.org/library/papers/31796685PubMed
31645300Evaluation of antihypertensive drugs in combination with enzyme replacement therapy in mice with Pompe disease.Mol Genet Metab2020https://conductscience.org/library/papers/31645300PubMed
31419653Engineered skeletal muscles for disease modeling and drug discovery.Biomaterials2019https://conductscience.org/library/papers/31419653PubMed

See all 45 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GAA2548PubTator's text mininghttps://conductscience.org/library/genes/2548NCBI Gene
IGF2R3482PubTator's text mininghttps://conductscience.org/library/genes/3482NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21397538

GET https://conductscience.org/api/papers/v1/21397538/references?page=2